Deep Learning to Differentiate Benign and Malignant Vertebral Fractures at Multidetector CT.

Journal: Radiology
PMID:

Abstract

Background Differentiating between benign and malignant vertebral fractures poses diagnostic challenges. Purpose To investigate the reliability of CT-based deep learning models to differentiate between benign and malignant vertebral fractures. Materials and Methods CT scans acquired in patients with benign or malignant vertebral fractures from June 2005 to December 2022 at two university hospitals were retrospectively identified based on a composite reference standard that included histopathologic and radiologic information. An internal test set was randomly selected, and an external test set was obtained from an additional hospital. Models used a three-dimensional U-Net encoder-classifier architecture and applied data augmentation during training. Performance was evaluated using the area under the receiver operating characteristic curve (AUC) and compared with that of two residents and one fellowship-trained radiologist using the DeLong test. Results The training set included 381 patients (mean age, 69.9 years ± 11.4 [SD]; 193 male) with 1307 vertebrae (378 benign fractures, 447 malignant fractures, 482 malignant lesions). Internal and external test sets included 86 (mean age, 66.9 years ± 12; 45 male) and 65 (mean age, 68.8 years ± 12.5; 39 female) patients, respectively. The better-performing model of two training approaches achieved AUCs of 0.85 (95% CI: 0.77, 0.92) in the internal and 0.75 (95% CI: 0.64, 0.85) in the external test sets. Including an uncertainty category further improved performance to AUCs of 0.91 (95% CI: 0.83, 0.97) in the internal test set and 0.76 (95% CI: 0.64, 0.88) in the external test set. The AUC values of residents were lower than that of the best-performing model in the internal test set (AUC, 0.69 [95% CI: 0.59, 0.78] and 0.71 [95% CI: 0.61, 0.80]) and external test set (AUC, 0.70 [95% CI: 0.58, 0.80] and 0.71 [95% CI: 0.60, 0.82]), with significant differences only for the internal test set ( < .001). The AUCs of the fellowship-trained radiologist were similar to those of the best-performing model (internal test set, 0.86 [95% CI: 0.78, 0.93; = .39]; external test set, 0.71 [95% CI: 0.60, 0.82; = .46]). Conclusion Developed models showed a high discriminatory power to differentiate between benign and malignant vertebral fractures, surpassing or matching the performance of radiology residents and matching that of a fellowship-trained radiologist. © RSNA, 2024 See also the editorial by Booz and D'Angelo in this issue.

Authors

  • Sarah C Foreman
    From the Department of Radiology and Biomedical Imaging (C.E.v.S., J.H.S., E.O., P.M.J., M.P., S.C.F., T.M.L., V.P.) and Department of Epidemiology and Biostatistics (F.L., M.C.N.), University of California, San Francisco, 185 Berry St, Suite 350, San Francisco, CA 94107; Department of Diagnostic and Interventional Radiology, Technische Universität München, Munich, Germany (C.E.v.S., S.C.F.); Department of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany (P.M.J.); and Department of Radiology, University of California Davis Health, Sacramento, Calif (L.N.).
  • David Schinz
    Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany; Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Malek El Husseini
    From the Departments of Radiology (S.C.F., A.S.D., G.C.F., M.R.M.) and Neuroradiology (D.S., M.E.H., M.R., M.C.M., B.W., B.J.S., J.S.K.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Departments of Radiology (S.S.G., J.W.) and Neuroradiology (R.S., A.S.G.), University Hospital Munich (LMU), Munich, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany (B.W.).
  • Sophia S Goller
    Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Jürgen Weißinger
    From the Departments of Radiology (S.C.F., A.S.D., G.C.F., M.R.M.) and Neuroradiology (D.S., M.E.H., M.R., M.C.M., B.W., B.J.S., J.S.K.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Departments of Radiology (S.S.G., J.W.) and Neuroradiology (R.S., A.S.G.), University Hospital Munich (LMU), Munich, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany (B.W.).
  • Anna-Sophia Dietrich
    From the Departments of Radiology (S.C.F., A.S.D., G.C.F., M.R.M.) and Neuroradiology (D.S., M.E.H., M.R., M.C.M., B.W., B.J.S., J.S.K.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Departments of Radiology (S.S.G., J.W.) and Neuroradiology (R.S., A.S.G.), University Hospital Munich (LMU), Munich, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany (B.W.).
  • Martin Renz
    From the Departments of Radiology (S.C.F., A.S.D., G.C.F., M.R.M.) and Neuroradiology (D.S., M.E.H., M.R., M.C.M., B.W., B.J.S., J.S.K.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Departments of Radiology (S.S.G., J.W.) and Neuroradiology (R.S., A.S.G.), University Hospital Munich (LMU), Munich, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany (B.W.).
  • Marie-Christin Metz
    From the Departments of Radiology (S.C.F., A.S.D., G.C.F., M.R.M.) and Neuroradiology (D.S., M.E.H., M.R., M.C.M., B.W., B.J.S., J.S.K.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Departments of Radiology (S.S.G., J.W.) and Neuroradiology (R.S., A.S.G.), University Hospital Munich (LMU), Munich, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany (B.W.).
  • Georg C Feuerriegel
    Department of Radiology, Klinikum Rechts Der Isar, School of Medicine, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany. georg.feuerriegel@tum.de.
  • Benedikt Wiestler
    Department of Neuroradiology, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Straße 22, 81675 Munich, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.
  • Robert Stahl
    Institut für Diagnostische und Interventionelle Neuroradiologie, Klinikum der Universität München-Großhadern, München, Deutschland.
  • Benedikt J Schwaiger
    Department of Neuroradiology, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany.
  • Marcus R Makowski
    School of Medicine and Health, Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, TUM University Hospital, Technical University of Munich, Munich, Germany.
  • Jan S Kirschke
    Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany.
  • Alexandra S Gersing
    From the Department of Radiology (C.E.v.S., V.S.S., Y.L., F.G.G., S.C.F., F.T.G., M.R.M., K.W., A.S.G.), Department for Orthopedics and Orthopedic Sports Medicine (N.J.W., C.K., R.v.E., R.B.), and Institute of Pathology (C.M.), Klinikum Rechts der Isar, Technische Universität München, Ismaninger Str 22, 81675 Munich, Germany; and the Department of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany (M.J., P.M.J., M.F.R.).